Merck was testing the injectable version of the world's biggest selling drug in a late stage trial of patients with a type of ...
The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free ...
Lucid Capital initiated coverage of InflaRx (IFRX) with a Buy rating and $10 price target InflaRx leverages its expertise in the complement ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback